check_circleStudy Completed

Amyloid Cardiomyopathy

Bayer Identifier:
AG10-201
ClinicalTrials.gov Identifier:
NCT03458130
EudraCT Number:
Not Available
EU CT Number:
Not Available
A Phase 2, Randomized, Placebo-controlled, Dose-ranging Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AG10 in Patients with Symptomatic Transthyretin Amyloid Cardiomyopathy

Trial purpose

Key Participants Requirements

Sex

N/A

Age

N/A
    -
    -

Trial summary

Enrollment Goal
N/A
Trial Dates
April 2018 - October 2018
Phase
Phase 2
Could I Receive a placebo
N/A
Products
Acoramidis (BAY3684938)
Accepts Healthy Volunteer
N/A

Trial design

A Phase 2, Randomized, Placebo-controlled, Dose-ranging Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AG10 in Patients with Symptomatic Transthyretin Amyloid Cardiomyopathy
Trial Type
Interventional
Intervention Type
N/A
Trial Purpose
N/A
Allocation
N/A
Blinding
N/A
Assignment
N/A
Trial Arms
N/A